<DOC>
	<DOCNO>NCT02538393</DOCNO>
	<brief_summary>The primary objective study • Investigate relative bioavailability sorafenib 400 mg ( 4 x 100 mg ) tablet oral suspension formulation comparison 400 mg ( 2 x 200 mg ) market tablet formulation . The secondary objective study - Evaluate dose proportionality sorafenib pharmacokinetics sorafenib tablet oral suspension formulation administration 200 mg ( 2 x 100 mg ) 400 mg ( 4 x 100 mg ) dose sorafenib fast state - Evaluate effect food pharmacokinetics tablet oral suspension formulation administration single dose 400 mg sorafenib ( 4 x 100mg ) - Evaluate taste palatability sorafenib ( formulation ) - Assess safety tolerability sorafenib tablet oral suspension healthy male subject</brief_summary>
	<brief_title>Relative Bioavailability Sorafenib Tablet Oral Suspension</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Healthy male subject age 18 ( inclusive ) 45 year ( inclusive ) first screen visit . Body mass index ( BMI ) 18.0 ( inclusive ) 32.0 kg / m² ( inclusive ) . Nonsmoker former smoker stop smoke least 3 month first study drug administration Ability understand follow studyrelated instruction Any subject sexually active man surgically sterilize must consent use condom intercourse ensure female partner practice adequate contraception , must willing refrain sexual intercourse begin trial 30 day last study drug administration . Medical surgical history : Failure major organ system medical disorder would impair subject 's ability complete study would alter absorption pharmacokinetics study drug Active infection medical , psychological social problem sufficient severity limit full compliance trial Known severe allergy , nonallergic drug reaction , multiple drug allergy History clinically significant metabolic , renal , hepatic , cardiovascular disease central nervous system disorder Clinically significant illness within 30 day first study drug administration . Febrile illness within 1 week first study drug administration Known hypersensitivity study drug Incompletely cure preexisting disease assume absorption , distribution , metabolism , elimination effect study drug normal Electrocardiogram ( ECG ) , blood pressure , heart rate : Clinically relevant finding ECG ( e.g . second thirddegree AV block , prolongation QRS complex 120 msec QTcinterval 450 msec ) Laboratory examination : Clinically relevant deviation screen laboratory parameter reference range ( especially gammaGT , ALT , AST , bilirubin ) Positive result hepatitis B virus surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) , human immune deficiency virus antibody ( antiHIV )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>